Novo Nordisk A/S (NYSE:NVO) Cut to Hold at Berenberg Bank

Berenberg Bank lowered shares of Novo Nordisk A/S (NYSE:NVO) from a buy rating to a hold rating in a report published on Wednesday, MarketBeat.com reports.

NVO has been the topic of a number of other reports. Zacks Research cut shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. Wall Street Zen downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, July 20th. Nordea Equity Research raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Friday, June 19th. Finally, HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Four research analysts have rated the stock with a Buy rating and sixteen have issued a Hold rating to the company’s stock. According to MarketBeat, Novo Nordisk A/S has an average rating of “Hold” and an average price target of $64.94.

Novo Nordisk A/S Trading Down 1.7%

NYSE:NVO opened at $45.91 on Wednesday. The stock’s 50 day simple moving average is $47.36 and its 200-day simple moving average is $44.51. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $64.16. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. The firm has a market cap of $204.99 billion, a P/E ratio of 11.23, a PEG ratio of 4.23 and a beta of 0.76.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. The company had revenue of $11.98 billion during the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 61.20%. Equities analysts anticipate that Novo Nordisk A/S will post 3.41 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a dividend, which will be paid on Tuesday, August 25th. Investors of record on Monday, August 17th will be given a dividend of $0.5786 per share. The ex-dividend date of this dividend is Monday, August 17th. This represents a yield of 254.0%. Novo Nordisk A/S’s dividend payout ratio is 42.79%.

Hedge Funds Weigh In On Novo Nordisk A/S

A number of hedge funds have recently made changes to their positions in NVO. Godfrey Financial Associates Inc. acquired a new stake in Novo Nordisk A/S during the 4th quarter worth approximately $25,000. Scarborough Advisors LLC purchased a new stake in Novo Nordisk A/S during the first quarter worth approximately $26,000. WealthCollab LLC increased its position in shares of Novo Nordisk A/S by 93.5% in the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after acquiring an additional 260 shares in the last quarter. Jackson Grant Investment Advisers Inc. acquired a new stake in shares of Novo Nordisk A/S in the fourth quarter worth $29,000. Finally, Quaker Wealth Management LLC boosted its position in Novo Nordisk A/S by 186.0% during the 4th quarter. Quaker Wealth Management LLC now owns 615 shares of the company’s stock worth $31,000 after purchasing an additional 400 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Oral Wegovy adoption is emerging as a potential catalyst. Jim Cramer highlighted accelerating pill prescriptions and argued that Wall Street’s initial negative reaction to Novo’s quarterly performance may have overlooked the company’s underlying strength. Jim Cramer Reevaluates Novo Nordisk as Wegovy Pill Adoption Accelerates
• Positive Sentiment: Unusually high call-option activity suggests some traders are positioning for a rebound: investors purchased roughly 100,752 calls, about 58% above typical volume. This is a market signal rather than a change in fundamentals.
• Positive Sentiment: Novo’s CEO Mike Doustdar said the obesity-drug market will not be dominated by a single company, arguing that patients will value differentiated treatments and that oral options could broaden demand. Novo CEO Says Obesity Market Won’t Be Winner-Take-All Battle With Lilly
• Neutral Sentiment: Zacks Research upgraded Novo Nordisk from “strong sell” to “hold,” indicating reduced bearishness but not a bullish recommendation. Erste Group also issued a fiscal-2026 earnings estimate, though no estimate details were provided.
• Negative Sentiment: Eli Lilly is gaining obesity-drug market share, creating concern that Lilly’s injectable and oral therapies could widen its competitive advantage even as Novo reports record prescriptions for oral Wegovy. Can Novo Nordisk’s GLP-1 Pill Momentum Offset Lilly’s Growing Edge?
• Negative Sentiment: The company’s chief executive acknowledged Lilly’s market-share gains, while an escalating marketing dispute highlights intensifying competition in the strategically important weight-loss market. Novo Nordisk Escalates Weight-Loss War With Eli Lilly

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.